论文部分内容阅读
目的探讨多西紫杉醇、顺铂、5-氟尿嘧啶与多西紫杉醇、顺铂联用后给予希罗达单药维持治疗晚期胃癌的临床效果及安全性比较。方法选择本院75例晚期胃癌患者作为研究对象,随机分为观察组(多西紫杉醇、顺铂、希罗达,n=38)和对照组(多西紫杉醇、顺铂、5-氟尿嘧啶,n=37)。通过近期疗效和远期临床效果如无进展生存(PFS)、治疗失败时间(TTF)和总生存时间(OS)等,以及毒副反应统计情况比较2组的疗效与不良反应情况。结果观察组的近期临床总有效率为52.6%,与对照组59.5%差异无统计学意义(P>0.05)。观察组和对照组的近期临床控制率分别为94.7%和86.5%。观察组在PFS和TTF时间上略好于对照组,但在OS上略低于对照组,各项指标比较2组差异均无统计学意义(P>0.05)。结论多西紫杉醇、顺铂联用后给予希罗达单药维持治疗效果肯定,副作用少,且无进展生存期较长,值得推广和应用。
Objective To compare the clinical efficacy and safety of cilostazol, cisplatin, 5-fluorouracil, docetaxel, and cisplatin combined with cilostasia in the treatment of advanced gastric cancer. Methods Seventy-five patients with advanced gastric cancer in our hospital were selected as study subjects and randomly divided into observation group (docetaxel, cisplatin, Xeloda, n=38) and control group (docetaxel, cisplatin, 5-fluorouracil, n =37). The curative effect and adverse reaction of the two groups were compared by the short-term efficacy and long-term clinical effects such as progression-free survival (PFS), treatment failure time (TTF) and total survival time (OS), and the toxicities and side effects statistics. Results The total clinical effective rate in the observation group was 52.6%, and there was no significant difference between the observation group and the control group (59.5%) (P>0.05). The recent clinical control rates in the observation and control groups were 94.7% and 86.5%, respectively. The observation group was slightly better in the time of PFS and TTF than the control group, but slightly lower in the OS than in the control group. There was no significant difference in the index between the two groups (P>0.05). Conclusion The combination of docetaxel and cisplatin combined with Xeloda alone has a definite effect on maintenance therapy, fewer side effects, and a longer progression-free survival period. It is worthy of promotion and application.